Related Experiment Video
Updated: Aug 24, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?
1Indiana University, Indianapolis, Indiana, USA. kathmill@iupui.edu
Abstract:
The central importance of angiogenesis and our understanding of how new blood vessels are formed have led to the development of novel antiangiogenic therapies. Although the number of agents in development has grown exponentially, only one phase III trial in breast cancer has been completed. In that study the addition of bevacizumab to capecitabine did not extend the progression-free survival of patients with refractory disease as compared with capecitabine monotherapy. Early enthusiasm for antiangiogenic therapy must give way to clinical reality. Our challenge now is to exploit better the activity of antiangiogenic agents seen in the early clinical studies.
Insights
Antiangiogenic therapies targeting new blood vessel formation show promise but require further clinical validation. A recent breast cancer trial found bevacizumab did not improve progression-free survival compared to standard chemotherapy.
Area of Science:
- Oncology
- Vascular Biology
Background:
- Angiogenesis, the formation of new blood vessels, is crucial in cancer growth.
- Novel antiangiogenic therapies have been developed based on this understanding.
Purpose of the Study:
- To evaluate the efficacy of antiangiogenic therapy in breast cancer.
- To assess the clinical reality of antiangiogenic agents in refractory disease.
Main Methods:
- A Phase III clinical trial was conducted.
- Bevacizumab was added to capecitabine chemotherapy for breast cancer patients with refractory disease.
Main Results:
- The addition of bevacizumab to capecitabine did not extend progression-free survival.
- Results were compared to capecitabine monotherapy.
Conclusions:
- Early enthusiasm for antiangiogenic therapy needs to be tempered by clinical trial outcomes.
- Further research is needed to optimize the use of antiangiogenic agents in cancer treatment.
More Related Videos
12:23Multi-modal Imaging of Angiogenesis in a Nude Rat Model of Breast Cancer Bone Metastasis Using Magnetic Resonance Imaging, Volumetric Computed Tomography and Ultrasound
Published on: August 14, 2012
07:45Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
